Oscar Tahuahua, Medical Oncology Fellow at the National Cancer Institute of Mexico, shared a post on X about a paper by Mariano Provencio et al. published in Nature Communications:
“In stage III NSCLC, sequence may matter more than we think.
APOLO ph2, open-label, single arm trial in unresectable stage III NSCLC showing that induction ChT-IO (atezo) before cCRT achieved a 1-year PFS of 68.4%, ↑ than historical PACIFIC rates (63% IIIB/C). 2-year OS was 60.5%, ORR after induction was 47.4% and G≥3 pneumonitis (2.6%).
The strongest signal was ctDNA clearance after induction.
Hypothesis-generating, but supports earlier IO and ctDNA-guided selection.”
Title: Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial
Authors: Mariano Provencio, Begoña Campos, María Guirado, Laia Vila, Rosario García Campelo, Miriam Dorta, Sergio Vázquez Estévez, Asia Ferrández, M. Ángeles Sala, Ana Laura Ortega, Ana Blasco, Amelia Insa, María Carmen Areses, Ivana Sullivan, Rafael Lopez, Virginia Calvo, Delvys Rodriguez-Abreu, Joaquim Bosch-Barrera, Ana López-Martín, Raquel Marsé, Laura Torrado, Kirill Matskov, Júlia Giner, Manuel Fernández Bruno, Emilio Sánchez Saugar, Cristina Martínez-Toledo, Pilar Mediavilla, Atocha Romero, Alberto Cruz-Bermúdez
You can read the Full Article in Nature Communications.
More posts featuring Oscar Tahuahua.